$4.08
+0.23
(+5.97%)▲
3.8%
Downside
Day's Volatility :3.8%
Upside
0.0%
17.89%
Downside
52 Weeks Volatility :78.19%
Upside
73.44%
Period | Accolade Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -51.2% | 6.5% | 0.0% |
6 Months | -68.31% | 7.1% | 0.0% |
1 Year | -72.79% | 9.8% | 0.0% |
3 Years | -92.01% | 14.2% | -20.2% |
Market Capitalization | 316.0M |
Book Value | $5.52 |
Earnings Per Share (EPS) | -1.16 |
Wall Street Target Price | 7.87 |
Profit Margin | -20.62% |
Operating Margin TTM | -26.3% |
Return On Assets TTM | -7.89% |
Return On Equity TTM | -20.01% |
Revenue TTM | 431.5M |
Revenue Per Share TTM | 5.67 |
Quarterly Revenue Growth YOY | 18.5% |
Gross Profit TTM | 165.3M |
EBITDA | -63.0M |
Diluted Eps TTM | -1.16 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.21 |
EPS Estimate Next Year | -1.13 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 92.89%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 94.8M | ↑ 23.41% |
Net Income | -56.5M | ↓ 7.82% |
Net Profit Margin | -59.59% | ↑ 20.18% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 132.5M | ↑ 39.76% |
Net Income | -51.4M | ↓ 9.08% |
Net Profit Margin | -38.76% | ↑ 20.83% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 170.4M | ↑ 28.57% |
Net Income | -50.7M | ↓ 1.39% |
Net Profit Margin | -29.73% | ↑ 9.03% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 310.0M | ↑ 81.98% |
Net Income | -123.1M | ↑ 143.08% |
Net Profit Margin | -39.71% | ↓ 9.98% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 363.1M | ↑ 17.13% |
Net Income | -459.7M | ↑ 273.32% |
Net Profit Margin | -126.58% | ↓ 86.87% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 414.3M | ↑ 14.09% |
Net Income | -99.8M | ↓ 78.29% |
Net Profit Margin | -24.09% | ↑ 102.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 99.0M | ↑ 8.88% |
Net Income | -30.4M | ↓ 23.67% |
Net Profit Margin | -30.73% | ↑ 13.11% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 93.2M | ↓ 5.86% |
Net Income | -38.4M | ↑ 26.21% |
Net Profit Margin | -41.2% | ↓ 10.47% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 96.9M | ↑ 3.9% |
Net Income | -32.8M | ↓ 14.54% |
Net Profit Margin | -33.89% | ↑ 7.31% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 99.4M | ↑ 2.59% |
Net Income | -21.1M | ↓ 35.83% |
Net Profit Margin | -21.2% | ↑ 12.69% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 124.8M | ↑ 25.62% |
Net Income | -7.5M | ↓ 64.36% |
Net Profit Margin | -6.01% | ↑ 15.19% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 110.5M | ↓ 11.51% |
Net Income | -27.6M | ↑ 267.55% |
Net Profit Margin | -24.98% | ↓ 18.97% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 65.8M | ↑ 39.68% |
Total Liabilities | 296.4M | ↑ 28.43% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 124.4M | ↑ 89.19% |
Total Liabilities | 148.2M | ↓ 50.0% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 475.5M | ↑ 282.2% |
Total Liabilities | 84.7M | ↓ 42.87% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 170.35% |
Total Liabilities | 429.7M | ↑ 407.59% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 903.1M | ↓ 29.75% |
Total Liabilities | 429.3M | ↓ 0.11% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 788.2M | ↓ 12.73% |
Total Liabilities | 342.7M | ↓ 20.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 903.1M | ↓ 1.17% |
Total Liabilities | 429.3M | ↑ 0.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 875.7M | ↓ 3.03% |
Total Liabilities | 421.5M | ↓ 1.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 854.3M | ↓ 2.44% |
Total Liabilities | 416.7M | ↓ 1.15% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 785.5M | ↓ 8.06% |
Total Liabilities | 350.8M | ↓ 15.82% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 788.2M | ↑ 0.34% |
Total Liabilities | 342.7M | ↓ 2.3% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 767.4M | ↓ 2.64% |
Total Liabilities | 332.1M | ↓ 3.09% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.5M | ↓ 56.78% |
Investing Cash Flow | -3.1M | ↓ 56.41% |
Financing Cash Flow | 48.8M | ↑ 224.71% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -34.2M | ↑ 106.96% |
Investing Cash Flow | -3.5M | ↑ 12.92% |
Financing Cash Flow | 28.2M | ↓ 42.21% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.2M | ↓ 26.32% |
Investing Cash Flow | -2.4M | ↓ 31.18% |
Financing Cash Flow | 428.4M | ↑ 1417.91% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -62.4M | ↑ 147.11% |
Investing Cash Flow | -263.6M | ↑ 10779.61% |
Financing Cash Flow | 257.9M | ↓ 39.79% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -40.7M | ↓ 34.72% |
Investing Cash Flow | -7.2M | ↓ 97.26% |
Financing Cash Flow | 3.2M | ↓ 98.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.6M | ↓ 45.46% |
Investing Cash Flow | -2.4M | ↑ 26.27% |
Financing Cash Flow | 418.0K | ↓ 73.99% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.3M | ↑ 653.69% |
Investing Cash Flow | -3.3M | ↑ 36.18% |
Financing Cash Flow | 4.5M | ↑ 964.83% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.0M | ↓ 58.32% |
Investing Cash Flow | -3.3M | ↑ 0.0% |
Financing Cash Flow | 641.0K | ↓ 85.6% |
Sell
Neutral
Buy
Accolade Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Accolade Inc | -37.19% | -68.31% | -72.79% | -92.01% | -87.04% |
![]() Solventum Corp | 13.4% | -16.71% | -16.71% | -16.71% | -16.71% |
![]() Veeva Systems Inc. | 1.24% | -10.63% | -7.18% | -43.19% | 9.43% |
![]() Ge Healthcare Technologies Inc. | 2.46% | 9.25% | 3.22% | 32.12% | 32.12% |
![]() Healthequity Inc | -3.68% | 3.76% | 26.99% | 6.89% | -2.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Accolade Inc | NA | NA | NA | -1.21 | -0.2 | -0.08 | NA | 5.52 |
![]() Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
![]() Veeva Systems Inc. | 54.35 | 54.35 | 1.35 | 4.76 | 0.13 | 0.06 | NA | 30.25 |
![]() Ge Healthcare Technologies Inc. | 23.5 | 23.5 | 20.11 | 4.27 | 0.22 | 0.06 | 0.0 | 16.23 |
![]() Healthequity Inc | 85.91 | 85.91 | 2.29 | 2.19 | 0.04 | 0.03 | NA | 24.11 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Accolade Inc | Buy | $316.0M | -87.04% | NA | -20.62% |
![]() Solventum Corp | Hold | $10.8B | -16.71% | NA | 15.73% |
![]() Veeva Systems Inc. | Buy | $29.8B | 9.43% | 54.35 | 22.34% |
![]() Ge Healthcare Technologies Inc. | Buy | $36.9B | 32.12% | 23.5 | 8.05% |
![]() Healthequity Inc | Buy | $6.9B | -2.18% | 85.91 | 7.71% |
Insights on Accolade Inc
Revenue is down for the last 2 quarters, 124.83M → 110.46M (in $), with an average decrease of 11.5% per quarter
Netprofit is down for the last 2 quarters, -7.50M → -27.59M (in $), with an average decrease of 267.6% per quarter
In the last 1 year, Healthequity Inc has given 27.0% return, outperforming this stock by 99.8%
In the last 3 years, Healthequity Inc has given 6.9% return, outperforming this stock by 98.9%
Brown Advisory Holdings Inc
BlackRock Inc
ARK Investment Management LLC
Vanguard Group Inc
JPMorgan Chase & Co
Bellevue Group AG
accolade is a personalized health and benefits solution that dramatically improves the experience, outcomes and cost of healthcare for employers, health plans and their members. with a unique blend of compassionate advisors, clinical experts and intelligent technologies, we engage individuals and families in their health, establish trust, and influence their decisions at every stage of care. we’ve been recognized as one of the nation’s 25 most promising companies by forbes magazine, the fastest-growing private healthcare company by inc. 500, and a top workplace by multiple news publications. for more information, visit www.accolade.com.
Organization | Accolade Inc |
Employees | 2400 |
CEO | Mr. Rajeev Singh |
Industry | Health Services |
A Spac I Acquisition Corp
$4.08
+5.97%
Keyarch Acquisition Corp
$4.08
+5.97%
Connexa Sports Technologies Inc
$4.08
+5.97%
Us Value Etf
$4.08
+5.97%
First Wave Biopharma Inc
$4.08
+5.97%
Global X Msci Next Emerging
$4.08
+5.97%
Fat Projects Acquisition Corp
$4.08
+5.97%
Capital Link Global Fintech
$4.08
+5.97%
Applied Uv Inc
$4.08
+5.97%